Evidence map›Paper›PMID 41122178›Full record

ArticleFrontiers in immunology2025

Development of potent HLA-A02:01-restricted peptide-based cytotoxic T-cells against SARS-CoV-2 infections in patients awaiting a kidney transplant.

Chih-Chao Chang, Ya Nan Liu, Zheng Xu, Elena-Rodica Vasilescu, Ping Li, Eric K Ho, Muyang Li, Syed A Husain, Govind Bhagat, Sumit Mohan and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chih-Chao ChangDepartment of Pathology and Cell Biology, Division of Immunogenetics and Cellular Immunology, Columbia University Irving Medical Center, New York, NY, United States.
Ya Nan LiuDepartment of Pathology and Cell Biology, Division of Immunogenetics and Cellular Immunology, Columbia University Irving Medical Center, New York, NY, United States.
Zheng XuDepartment of Pathology and Cell Biology, Division of Immunogenetics and Cellular Immunology, Columbia University Irving Medical Center, New York, NY, United States.
Elena-Rodica VasilescuDepartment of Pathology and Cell Biology, Division of Immunogenetics and Cellular Immunology, Columbia University Irving Medical Center, New York, NY, United States.
Ping LiDepartment of Pathology and Cell Biology, Division of Immunogenetics and Cellular Immunology, Columbia University Irving Medical Center, New York, NY, United States.
Eric K HoDepartment of Pathology and Cell Biology, Division of Immunogenetics and Cellular Immunology, Columbia University Irving Medical Center, New York, NY, United States.
Muyang LiDepartment of Pathology and Cell Biology, Division of Immunogenetics and Cellular Immunology, Columbia University Irving Medical Center, New York, NY, United States.
Syed A HusainDepartment of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, NY, United States.
Govind BhagatDepartment of Pathology and Cell Biology, Division of Hematopathology, Columbia University Irving Medical Center, New York, NY, United States.
Sumit MohanDepartment of Medicine, Division of Nephrology, Columbia University Irving Medical Center, New York, NY, United States.
George VladDepartment of Pathology and Cell Biology, Division of Immunogenetics and Cellular Immunology, Columbia University Irving Medical Center, New York, NY, United States.
Nicole Suciu-FocaDepartment of Pathology and Cell Biology, Division of Immunogenetics and Cellular Immunology, Columbia University Irving Medical Center, New York, NY, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Controlling viral infections prior to solid organ transplantation is vital for successful engraftment and overall well-being of patients. One promising approach involves the deployment of viral antigen-specific cytotoxic T cells to eradicate viral pathogens. Although there have been attempts to develop anti-viral vaccines in the literature, the limited number of virus-specific cells which can be generated Methods: We developed a straightforward and scalable method for the Results: Using A2/S Conclusion: Our study demonstrates that viral antigen-specific cytotoxic CD8

Indexed as

COVID-19HLA-A2 AntigenKidney TransplantationSARS-CoV-2Spike Glycoprotein, CoronavirusT-Lymphocytes, CytotoxicAdultAgedCD8-Positive T-LymphocytesFemaleHumansMaleMiddle AgedPeptidesHLA-A*02:01 antigenHLA-A2 AntigenPeptidesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antigen specific-cytotoxic T cellscell-mediated immunityCOVID-19immunophenotypingorgan transplantSARS-CoV-2T-cell therapytetramer

Identifiers

PMID41122178
PMCPMC12535972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.